PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics. Dr. Rosenberg’s work has focused on immune tolerance induction and immunogenicity. ...

PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies peptide epitopes associated with T cell immunity to SARS-CoV-2 and confirms that recovering patients produce a memory immune response to iVAX-predicted ...

PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method of survival analysis for cancer patients using EVT’s Ancer platform. EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools ...

PROVIDENCE, RI, April 27, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs” in Frontiers in Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administration of IgG-derived Tregitopes were found to induce suppressive antigen-specific T-regulatory cells in ovalbumin (OVA) and ragweed-allergic murine ...

PROVIDENCE, RI, February 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the EU and India) with the aim of developing next-generation influenza vaccines with better responsiveness, lower costs, ...

PROVIDENCE, R.I., Dec. 31, 2020 /PRNewswire/ — EpiVax (“EpiVax”) and EpiVax Therapeutics (“EVT”) today provide an update on the advancement of their peptide-based COVID-19 vaccine, EPV-CoV-19. EPV-CoV-19, a T cell epitope-based vaccine designed by EpiVax’s scientists in February 2020 and licensed to EVT in August 2020, has completed IND-enabling preclinical validation studies and is making steady progress towards a clinical trial, anticipated in ...

PROVIDENCE, R.I., Dec. 29, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today provides an update on the advancement of the company’s peptide therapeutic immunogenicity assessment program. The PANDA (Peptide Abbreviated New Drug Application) immunogenicity assessment program was originally developed for screening generic peptide drugs and their impurities following the publication of the ANDA draft guidance by the Food and Drug Administration ...

PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020 than ever before in the company’s twenty-two years of business. EpiVax first developed the ISPRI toolkit in 2006 to enable ...

PROVIDENCE, RI, October 22, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and CUBRC, Inc. (“CUBRC”) announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) in response to a Broad Agency ...

PROVIDENCE, RI, August 24, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”), a Rhode Island-based company and recognized leader in the field of computational vaccinology, today announced it has out-licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics (“EVT”), a New York-based company previously named EpiVax Oncology.   Scientists at EpiVax designed EPV-CoV-19 – a peptide-based, epitope-driven vaccine – ...

Six months in, are we any closer to a vaccine?

Press Release: EpiVax Announces Licensing of Immunogenicity Screening Toolkit, ISPRI, to AbCellera

Press Release: Intravacc and EpiVax team up in development of COVID-19 emerging vaccine

HONG KONG, May 1, 2020 (Newswire.com) – Pacific GeneTech (PGT), a biologics company that develops and commercializes next-generation vaccines for areas of high unmet or underserved needs in animal health and food safety, is collaborating with Rhode Island-based EpiVax, an informatics & immunology company, to develop a novel vaccine for African Swine Fever. African Swine Fever (ASF) ...

EDMONTON, Alberta, April 28, 2020 — Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development. This partnership will combine the Entos ...